FDA
-
Preparing for Changes to ICH GCP E6(R3) and ICH E8(R1) – Readying for Risk MitigationSandra “SAM” SatherOn-Demand00
-
FDA REMS Inspection Guide: Audit Preparedness Best PracticesPenelope Przekop, MSQA, RQAP-GCPOn-Demand00
-
The MHRA Data Integrity Guidance Clarified: What it Means for Industry & PatientsBetsy FallenOn-Demand20
-
How FDA and MHRA Decide Which Drug Facilities to Inspect – and at What FrequencyJerry ChapmanOn-Demand10
-
A Holistic Approach to External GMP Surveillance, GMP Training, and Quality Knowledge ManagementJerry ChapmanOn-Demand00
-
00
-
Note to File 101: Critical Steps for When, and When Not To, Engage in NTFsLuisa Monica, Jackie MorrillOn-Demand00
-
00
-
00
$1,799.00$1,199.00 -
00
-
Investigator Oversight Plans: Essentials for Inspection Readiness Post ICH GCP E6 (R2) AddendumSandra “SAM” SatherOn-Demand00
-
CAPA and Root Cause Analysis: Essentials Post ICH GCP E6 (R2) AddendumSandra “SAM” SatherOn-Demand00
-
00
-
-
Certified Copies and ALCOA-C: Essentials Post ICH GCP E6 (R2) AddendumSandra “SAM” SatherOn-Demand00
-
00